Project Grant R43AG092066
Award Date
7/1/25
Completion Date
6/30/26
Dollars Obligated
$498K
Federal Agency
National Institute on Aging
Awardee
Einsenca Inc. (J2PGQ6JNTVS9)
Federal Grant Program
93.866
Assistance Type
Project Grant
Place of Performance
Delaware, USA
Similar Awards
This Project Grant from the National Institutes of Health's National Institute on Aging, under the Aging Research program (CFDA 93.866), provides $2,969,644 to develop a novel positron emission tomography (PET) imaging probe targeting myeloperoxidase (MPO) activity for detecting neuroinflammation in neurodegenerative diseases. The Massachusetts General Hospital will design and screen potential PET agents for detecting MPO activity in the brain, characterize and validate candidate MPO PET...
This federal Project Grant award from the National Institute on Aging (NIA), under the Aging Research program (CFDA 93.866), provides $1,247,875 to Yale University to characterize the properties and performance of the PET radiotracer [18F]3F4AP for detecting and quantifying demyelination and cerebral perfusion in subjects with Alzheimer's disease (AD), mild cognitive impairment (MCI), and cognitively normal individuals. The research aims to perform the first full pharmacokinetic evaluation of...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $455,009 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to develop a novel [18F]-labeled amphiphilic PET probe that can cross the blood-brain barrier and track CD206+ microglia/macrophages in Alzheimer's disease. The goal is to create a non-invasive imaging method to detect anti-inflammatory M2-like microglia and macrophages, which play a key role in...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) will fund the development of a novel Alzheimer's disease therapeutic using targeted nanoparticles. The $504,732 award to Aphios Corp, a minority-owned biotechnology company, will support two phases of research. In Phase I, the company will nanoencapsulate an anti-CCR5 drug in targeted and non-targeted nanoparticles, characterize the formulations, and evaluate their impact on in vitro models of brain...
The National Institute on Aging (NIA) awarded a $1,783,700.00 Project Grant under the Aging Research program (CFDA 93.866) to the University of Illinois to develop novel blood-brain barrier permeable multimodal imaging agents for the diagnosis of neurodegenerative diseases, with a focus on Alzheimer's disease and related dementias. The 3-year grant aims to employ organic and inorganic chemical design principles to generate diagnostic agents capable of detecting protein aggregation,...
This Project Grant award from the National Institute on Aging's (NIA) Aging Research program (CFDA 93.866) provides $3,038,050 to the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University to study the molecular mechanisms of Alzheimer's disease. The funded research aims to discover a novel oxidative stress pathway that targets microglia, the immune cells in the brain, leading to their dysfunction and detrimental consequences in Alzheimer's disease. The goal is to develop...
This Project Grant award from the National Institute on Aging (NIA) under CFDA 93.866 Aging Research provides $812,030 to develop and optimize non-invasive imaging biomarkers to track neuroinflammation in the early stages of Alzheimer's disease (AD). The research aims to investigate the relationship between astrocytic acetate metabolism and astrocyte reactivity, characterize spatiotemporal patterns of neuroinflammation and brain glucose hypometabolism in an AD mouse model, and validate the...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $782,495 to Emory University to develop a novel positron emission tomography (PET) ligand that can quantify poly(ADP-ribose) polymerase-1 (PARP1) expression in the living brain. PARP1 dysregulation has been implicated in Alzheimer's disease and other neurodegenerative disorders, but no successful PARP1 brain imaging agents have been demonstrated to date. The project aims to optimize a lead...
The National Institute on Aging (NIA) awarded a $842,175 Project Grant under the Aging Research program (CFDA 93.866) to the J. David Gladstone Institutes in San Francisco, CA. The grant, awarded on December 15, 2024, will fund research to explore the role of the NOX2 enzyme in mediating Alzheimer's disease (AD) pathologies, including network hyperactivity, glucose hypometabolism, and accumulation of amyloid-beta and tau proteins. The research aims to assess the therapeutic efficacy of a novel...
This federal Project Grant award of $513,740.00 was provided by the National Institute on Aging (NIA), under the Aging Research program (CFDA 93.866), to develop a novel exosome-based nano-scavenger (EBNS) for the targeted removal of amyloid-beta (Aβ) proteins associated with Alzheimer's disease (AD) and other amyloid-related disorders. The 3-year project aims to: 1) genetically engineer exosomes to load Aβ-targeting antibodies and Aβ-degrading enzymes; 2) establish isolation and...